![]() |
|
|
Vol. 297, Issue 1, 57-68, April 2001
Division of Nephrology and Hypertension, University of Bern, Bern,
Switzerland (C.D., K.S.-N., N.L., H.-P.M.); Center for Inflammation
Research, University of Edinburgh, Edinburgh, United Kingdom (J.D.);
and Institute of Pathology, University of Bern, Bern, Switzerland
(T.B.)
Inflammation is characterized by an excess of cell proliferation often
leading to fibrosis and sclerosis with subsequent loss of organ
function. We hypothesized that these features may be ameliorated by
induction of cell cycle arrest and apoptosis as result of therapy with
matrix metalloproteinase (MMP) inhibitors. In our study, mesangial
cells and experimental mesangial proliferative glomerulonephritis
provided the model of inflammation. First, we investigated the effect
of the MMP inhibitor BB-1101 in anti-Thy1.1 nephritis. The numbers of
apoptotic glomerular cells in nephritic rats increased about 4 and 6 times as a result of BB-1101 therapy, observed 11 and 14 days
after induction of disease, respectively. Subsequently, rat mesangial
cells were exposed to an MMP inhibitor in vitro. Fluorescence-activated
cell sorter analyses of cells exposed to RO111-3456 demonstrated
a dose-dependent cell cycle arrest in the G0/G1
phase associated with increased expression of statin. The cell cycle
arrest was followed by apoptosis as investigated by terminal
deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate
(dUTP) biotin nick-end labeling (TUNEL) and acridine orange/ethidium
bromide stainings, as well as by annexin V binding. The induction of
p53, p21, and bax, but not the Fas/FasL pathway appeared to play an
important pathogenetic role. In summary, MMP inhibitors induce cell
cycle arrest followed by apoptosis in mesangial cells. These features
help to explain the anti-inflammatory effects of these compounds, such
as reduction of mesangial cell proliferation and attenuation of
extracellular matrix accumulation. In conclusion, induction of cell
cycle arrest with subsequent apoptosis may offer new perspectives in
the therapy of inflammation even beyond kidney diseases.
This article has been cited by other articles:
![]() |
G. Tuffin, E. Waelti, J. Huwyler, C. Hammer, and H.-P. Marti Immunoliposome Targeting to Mesangial Cells: A Promising Strategy for Specific Drug Delivery to the Kidney J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3295 - 3305. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Lods, P. Ferrari, F. J. Frey, A. Kappeler, C. Berthier, B. Vogt, and H.-P. Marti Angiotensin-Converting Enzyme Inhibition but not Angiotensin II Receptor Blockade Regulates Matrix Metalloproteinase Activity in Patients with Glomerulonephritis J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2861 - 2872. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. M. Adhami, N. Ahmad, and H. Mukhtar Molecular Targets for Green Tea in Prostate Cancer Prevention J. Nutr., July 1, 2003; 133(7): 2417S - 2424. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Alhasan, O. Aranha, and F. H. Sarkar Genistein Elicits Pleiotropic Molecular Effects on Head and Neck Cancer Cells Clin. Cancer Res., December 1, 2001; 7(12): 4174 - 4181. [Abstract] [Full Text] [PDF] |
||||